Binds Antigen Or Epitope Whose Amino Acid Sequence Is Disclosed In Whole Or In Part (e.g., Binds Specifically-identified Amino Acid Sequence, Etc.) Patents (Class 424/139.1)
-
Patent number: 11965029Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.Type: GrantFiled: June 4, 2021Date of Patent: April 23, 2024Assignee: Amgen Inc.Inventors: Dirk E. Smith, Ian Foltz, Chadwick T. King, Ai Ching Lim, Rutilio Clark, Michael R. Comeau, Randal R. Ketchem, Donghui Shi, Xiaoshan Min, Zhulun Wang
-
Patent number: 11946935Abstract: Methods and diagnostic compositions for detecting and monitoring meningiomas.Type: GrantFiled: August 25, 2021Date of Patent: April 2, 2024Assignee: Regents of the University of MinnesotaInventors: Nurten Saydam, Okay Saydam
-
Patent number: 11944596Abstract: Embodiments of the disclosure are drawn to an enteral feeding device for hydrolyzing triglycerides in a nutritional formula. The device may include a body housing a chamber, an inlet configured to fluidly couple with a source of nutritional formula, and an outlet configured to fluidly couple with an enteral feeding tube. The device may include a headspace and a plurality of particles contained within the chamber, wherein the lipase is covalently bonded to the plurality of particles. The device may include an inlet filter located between the inlet and the chamber, wherein the inlet filter contains a first plurality of openings, and an outlet filter located between the chamber and the outlet, wherein the outlet filter has a second plurality of openings smaller than the plurality of particles.Type: GrantFiled: May 27, 2021Date of Patent: April 2, 2024Assignee: Alcresta Therapeutics, Inc.Inventors: Robert Gallotto, Greta L. Loring, Kenneth Gary, Edward S. Park, David J. Brown, Willem Robert Klaas Schoevaart, Michiel Christian Alexander van Vliet
-
Patent number: 11939387Abstract: The present invention discloses an antibody capable of binding to human interleukin 4 receptor alpha (hIL-4R alpha) and a preparation method and application thereof. The anti-hIL-4R alpha antibody can specifically bind to hIL-4R alpha, has good effects for inhibiting IL-4 and IL-13-induced cell line proliferation and the like, and can be applied to treatment of IL-4R alpha related diseases, such as immune-mediated inflammatory diseases.Type: GrantFiled: October 17, 2022Date of Patent: March 26, 2024Assignee: SHANGHAI MABGEEK BIOTECH. CO., LTDInventors: Chenghai Zhang, Jinlin Guo, Yujing Yuan
-
Patent number: 11912769Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.Type: GrantFiled: January 25, 2022Date of Patent: February 27, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Xavier Valencia, John P. Throup, Steven G. Nadler, Suzanne J. Suchard, Dominique Duchesne, Xiaoni Liu, Rong Shi, Diane E. Shevell, Jenny H. Xie, Marek Honczarenko
-
Patent number: 11911357Abstract: Embodiments of the disclosure are drawn to an enteral feeding device for hydrolyzing triglycerides in a nutritional formula. The device may include a body housing a chamber, an inlet configured to fluidly couple with a source of nutritional formula, and an outlet configured to fluidly couple with an enteral feeding tube. The device may include a headspace and a plurality of particles contained within the chamber, wherein the lipase is covalently bonded to the plurality of particles. The device may include an inlet filter located between the inlet and the chamber, wherein the inlet filter contains a first plurality of openings, and an outlet filter located between the chamber and the outlet, wherein the outlet filter has a second plurality of openings smaller than the plurality of particles.Type: GrantFiled: May 27, 2021Date of Patent: February 27, 2024Assignee: Alcresta Therapeutics, Inc.Inventors: Robert Gallotto, Greta L. Loring, Kenneth Gary, Edward S. Park, David J. Brown, Willem Robert Klaas Schoevaart, Michiel Christian Alexander van Vliet
-
Patent number: 11896667Abstract: The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.Type: GrantFiled: September 14, 2020Date of Patent: February 13, 2024Assignee: UCB PHARMA S.A.Inventor: Martyn K. Robinson
-
Patent number: 11892450Abstract: The invention provides assay methods of detecting plasma protease CI inhibitor (C1-INH) that binds plasma kallikrein, Factor XII, or both, and uses thereof for identifying subjects at risk for or suffering from a pKal-me-diated or bradykinin-mediated disorder. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment.Type: GrantFiled: May 22, 2020Date of Patent: February 6, 2024Assignee: Takeda Pharmaceutical Company LimitedInventors: Kusumam Joseph, Allen P. Kaplan
-
Patent number: 11891446Abstract: The present invention is directed toward monoclonal antibodies that bind to death receptor 4 and/or death receptor 5, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.Type: GrantFiled: February 2, 2021Date of Patent: February 6, 2024Assignee: GALAXY BIOTECH, LLCInventors: Kyung Jin Kim, Hangil Park, Lihong Wang, Yi Ding, April Zhang, Maximiliano Vasquez
-
Patent number: 11884720Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human MSLN on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.Type: GrantFiled: August 1, 2016Date of Patent: January 30, 2024Assignees: AMGEN RESEARCH (MUNICH) GMBH, AMGEN INC.Inventors: Tobias Raum, Jonas Anlahr, Julie Bailis, Claudia Blümel, Patrick Hoffmann, Peter Kufer, Elisabeth Nahrwold, Doris Rau
-
Patent number: 11873337Abstract: The invention relates to an antibody which binds to cell adhesion molecule 3 (CADM3) or an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment thereof, a nucleic acid comprising a nucleotide sequence encoding the antibody or the antibody fragment thereof, a transformant cell comprising a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment thereof, a composition comprising the antibody or the antibody fragment thereof, and a method for detecting or measuring an antigen present in the brain, a method for diagnosing or treating a brain disease, a method for enhancing the property of accumulating in a brain of an antibody, and a method for increasing the amount of an antibody in the brain, each of which using the antibody or the antibody fragment thereof, and the like.Type: GrantFiled: June 26, 2019Date of Patent: January 16, 2024Assignees: KYOWA KIRIN CO., LTD., KAGOSHIMA UNIVERSITYInventors: Nobuaki Takahashi, Ryosuke Nakano, Sayaka Maeda, Takenao Yamada, Yuji Ito
-
Patent number: 11866500Abstract: Disclosed is the use of a combination of an anti-PD-1 antibody and a VEGFR inhibitor in the preparation of a drug for treating cancers.Type: GrantFiled: November 12, 2021Date of Patent: January 9, 2024Assignees: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.Inventors: Xing Sun, Guoqing Cao, Changyong Yang, Lianshan Zhang, Yong Guo
-
Patent number: 11866511Abstract: The invention relates to anti-ganglioside GD2 antibodies that comprise an antibody variable domain and antibody constant domains, wherein the variable domain comprises a heavy and light chain variable region comprising respectively at least the CDR3 of the heavy chain variable region of antibody ch14.18 and at least the CDR3 of the light chain variable region of antibody ch14.18; and an IgA hinge and CH2 domain and to methods of treatment of subjects with a GD2 positive tumor, preferably neuroblastoma with these antibodies.Type: GrantFiled: March 20, 2020Date of Patent: January 9, 2024Assignee: TigaTX, Inc.Inventors: Jeanette Henrica Wilhelmina Leusen, Johannes Gerardus Maria Evers
-
Patent number: 11859002Abstract: The present invention relates to antagonistic TNFR2 polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T-regs) and/or expand T effector cell populations or function. For example, antibodies of the invention include antagonistic TNFR2 antibodies and antigen-binding fragments thereof, and can be used to suppress the T-reg-mediated deactivation of tumor reactive T-lymphocytes, as well as to treat a wide variety of cancers and infectious diseases.Type: GrantFiled: May 12, 2017Date of Patent: January 2, 2024Assignee: The General Hospital CorporationInventor: Denise L. Faustman
-
Patent number: 11851488Abstract: Described herein are novel anti-CD3 antibodies conjugated to folate and uses thereof treatment of diseases or conditions that would benefit from such conjugate are provided.Type: GrantFiled: November 2, 2016Date of Patent: December 26, 2023Assignee: Ambrx, Inc.Inventors: Harun Rashid, Feng Tian, Marco Gymnopoulos
-
Patent number: 11839654Abstract: The present invention provides a method of treating a tau-mediated cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of an anti-Tau antibody and an effective amount of an OGA inhibitor.Type: GrantFiled: January 5, 2021Date of Patent: December 12, 2023Assignee: Eli Lilly and CompanyInventors: Mansuo Lu Hayashi, Michael Carl Irizarry, Hugh Nuthall
-
Patent number: 11835531Abstract: An in vitro method for the prognosis of an adverse event in asymptomatic subjects comprising the determination of the level of Procalcitonin (PCT) or a fragment thereof or a precursor or fragment thereof having at least 12 amino acid residues in a sample of a bodily fluid from the subject and the correlation of the determined level to a potential risk of sustaining an adverse event.Type: GrantFiled: April 8, 2019Date of Patent: December 5, 2023Assignee: B.R.A.H.M.S GmbHInventors: Joachim Struck, S. J. L. Bakker
-
Patent number: 11834497Abstract: Antibodies and compositions against GLUT4 and uses thereof are provided herein.Type: GrantFiled: April 30, 2019Date of Patent: December 5, 2023Assignee: INTEGRAL MOLECULAR, INC.Inventors: David F. Tucker, Kimberly-Anne Mattia, Christine R. Fisher, Benjamin J. Doranz, Joseph B. Rucker
-
Patent number: 11820822Abstract: The present invention is based, in part, on the identification of biomarkers, and methods of modulate thereof, for sensitizing cancer cells to T cell-mediated killing. For example, the present invention, in part, comprises methods of sensitizing cancer cells in a subject afflicted with a cancer to cytotoxic T cell-mediated killing comprising administering to a subject a therapeutically effective amount of an agent that modulates the biomarker.Type: GrantFiled: June 5, 2018Date of Patent: November 21, 2023Assignee: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Deng Pan, Kai W. Wucherpfennig
-
Patent number: 11820820Abstract: An antibody capable of blocking CD47-SIRPa interaction and an application thereof.Type: GrantFiled: June 10, 2019Date of Patent: November 21, 2023Assignee: CHENGDU CONMED BIOSCIENCES CO., LTD.Inventors: Bo Chen, Gang Xu, Xuhong Chen, Feng Li, Boyan Zhang, Sijia Huang
-
Patent number: 11814654Abstract: The present invention relates to the prevention or treatment of skeletal growth retardation disorders, in particular skeletal diseases developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a prolonged activated mutant of FGFR3. More particularly, the present invention relates to a soluble FGFR3 for use in the prevention or treatment of achondroplasia.Type: GrantFiled: June 19, 2020Date of Patent: November 14, 2023Assignees: Institut National de la Sante et de la Recherche Medicale, Université Paul Sabatier Toulouse IIIInventor: Elvire Gouze
-
Patent number: 11807685Abstract: Disclosed is an antibody that selectively binds CD47 on tumor cells. Also disclosed is a method for treating cancer in a subject, comprising administering to the subject an effective amount of the antibody disclosed.Type: GrantFiled: August 4, 2022Date of Patent: November 7, 2023Assignee: The UAB Research FoundationInventor: Xiaoguang Margaret Liu
-
Patent number: 11773173Abstract: In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject with or potentially with atopic dermatitis, at 0.1 to 1000 mg/body/1 day to 12 weeks, preferably at 0.1 to 1000 mg/body/2 weeks, 0.1 to 1000 mg/body/4 weeks, or 0.1 to 1000 mg/body/8 weeks.Type: GrantFiled: December 13, 2019Date of Patent: October 3, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Akihisa Kaneko, Yuki Iwayanagi, Hidetomo Kitamura, Yoshinobu Higuchi, Hiroaki Matsushita, Ryosuke Mihara, Yumi Yamamoto, Tomohisa Saito, Keiko Hirokawa
-
Patent number: 11767369Abstract: The present invention provides molecules, including proteins, more particularly, immunoglobulins whose in vivo half-lives are altered (increased or decreased) by the presence of an IgG constant domain, or FcRn binding fragment thereof (e.g., an Fc region or hinge-Fc region) (e.g., from a human IgG, e.g., human IgG1), that have modifications of one or more of amino acid residues in at least the CH3 domain.Type: GrantFiled: September 10, 2019Date of Patent: September 26, 2023Assignee: MedImmune, LLCInventors: Ping Tsui, Martin Borrok, William Dall'Acqua, Yanli Wu, Nurten Beyaz-Kavuncu
-
Patent number: 11752205Abstract: A vaccine vector comprising a first polynucleotide encoding the antigenic polypeptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or any combination thereof.Type: GrantFiled: September 20, 2022Date of Patent: September 12, 2023Inventors: Sherryll Layton, Jeffrey W. Hall
-
Patent number: 11739441Abstract: The present invention relates to a library of particles, the library displaying a plurality of different T cell receptors (TCRs), wherein the plurality of TCRs consists essentially of TCRs comprising an alpha chain comprising an alpha chain variable domain and a beta chain comprising a beta chain variable domain and the library comprises more than one TRAV gene product and/or more than one TRBV gene product, wherein the beta chain variable domain does not comprise one or more of a TRBV5-1, 5-3, 5-4, 5-5, 5-6, 5-7 or 5-8 gene product and wherein the plurality of TCRs do not consist essentially of TCRs comprising a TRAV12-2 gene product from a natural repertoire and a TRBV6 gene product from a natural repertoire and TCRs comprising a TRAV21 gene product from a natural repertoire and a TRBV6 gene product from a natural repertoire.Type: GrantFiled: August 18, 2021Date of Patent: August 29, 2023Assignee: Immunocore LimitedInventors: Peter Eamon Molloy, Arsen Valeryevich Volkov, Dhaval Jaykant Sangani, Graham Anthony Hood, Chandramouli Reddy Chillakuri
-
Patent number: 11739442Abstract: The present invention relates to a library of particles, the library displaying a plurality of different T cell receptors (TCRs), wherein the plurality of TCRs consists essentially of TCRs comprising an alpha chain variable domain and a beta chain variable domain, wherein the alpha chain variable domain comprises a TRAV12-2 gene product and the beta chain variable domain comprises a TRBV gene product.Type: GrantFiled: August 19, 2021Date of Patent: August 29, 2023Assignees: Immunocore Limited, Adaptimune LimitedInventors: Bent Karsten Jakobsen, Nathaniel Ross Liddy, Peter Eamon Molloy, Annelise Brigitte Vuidepot
-
Patent number: 11725045Abstract: Provided are antibodies or antigen binding polypeptides characterized by the ability to neutralize respiratory syncytial virus (RSV). Specifically, the antibodies or antigen binding polypeptides are characterized by high affinity binding to RSV fusion glycoprotein (RSVF). Further provided are methods for their identification, isolation, generation, preparation, and use, as well as the heavy chain and light chain sequences of the antibodies provided.Type: GrantFiled: October 12, 2018Date of Patent: August 15, 2023Assignee: Mapp Biopharmaceutical, Inc.Inventor: Laura M. Walker
-
Patent number: 11725052Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human PAR-2 and compositions comprising such antibodies or antigen-binding fragments thereof. In a particular aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human PAR-2 block the interaction between a PAR-2 activating ligand and an extracellular domain of PAR-2, and/or blocks PAR-2 activation by a PAR-2 activating ligand, In further aspects, the antibodies or antigen-binding fragments can be used to treat diseases or conditions associated with increased expression of PAR-2 and/or diseases or conditions that can be alleviated by antagonizing activation of PAR-2 by a PAR-2 activating ligand (e.g., airway diseases, skin diseases, cancer, orofacial granulomatosis, inflammatory conditions, and pain associated with various diseases or conditions).Type: GrantFiled: August 18, 2021Date of Patent: August 15, 2023Assignee: Cephalon LLCInventors: Anna Mikaela Bracken, Adam Clarke, Bridget A. Cooksey, Anthony Gerard Doyle, Mark Terence Liddament, Matthew Pollard, Lynn Poulton, Anna Maria Matilda Quigley, Julia Rozenfeld, Marta Szabat
-
Patent number: 11708600Abstract: Differential expression of long non-coding RNAs (lncRNAs) and enhancer RNAs (eRNAs) are used to diagnose diseases including neurological diseases, inflammatory diseases, rheumatic diseases, and autoimmune diseases. Machine learning systems are used to identify lncRNAs or eRNAs having differential expression correlated with certain disease states.Type: GrantFiled: June 18, 2018Date of Patent: July 25, 2023Assignee: DECODE HEALTH, INC.Inventor: Charles Floyd Spurlock, III
-
Patent number: 11708419Abstract: The present invention relates to subcutaneous formulations of anti-CD38 antibodies and their uses.Type: GrantFiled: December 9, 2020Date of Patent: July 25, 2023Assignee: JANSSEN BIOTECH, INC.Inventors: Richard Jansson, Vineet Kumar
-
Patent number: 11708420Abstract: The present invention relates to subcutaneous formulations of anti-CD38 antibodies and their uses.Type: GrantFiled: December 9, 2020Date of Patent: July 25, 2023Assignee: JANSSEN BIOTECH, INC.Inventors: Richard Jansson, Vineet Kumar
-
Patent number: 11702642Abstract: The present invention relates to the prevention or treatment of skeletal growth retardation disorders, in particular skeletal diseases developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3. More particularly, the present invention relates to a soluble FGFR3 for use in the prevention or treatment of achondroplasia.Type: GrantFiled: March 13, 2020Date of Patent: July 18, 2023Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paul Sabatier Toulouse IIIInventor: Elvire Gouze
-
Patent number: 11697680Abstract: The present invention relates to antigen-binding molecules, preferably antibodies or antigen-binding fragments thereof, that specifically bind to a GP73, or to an antigenic portion thereof, wherein the antigen-binding molecule binds to an epitope within the extracellular part of GP73 that is internalized into a cell usually subsequent to proteolytic cleavage. The invention further relates to immunoconjugates comprising the antigen-binding molecules, in particular the anti-GP73 antibodies, or antigen-binding fragments thereof. The antigen-binding molecules and immunoconjugates of the invention may be administered alone, as a therapeutic conjugate or in combination with other naked antibodies, or with therapeutic agents, or with other immunoconjugates or as a diagnostic conjugate. The present invention also relates to nucleotide sequences encoding anti GP73 antibodies, and immunoconjugates, vectors and host cells containing the nucleotide sequences, and methods of making anti-GP73-antibodies.Type: GrantFiled: November 21, 2017Date of Patent: July 11, 2023Assignee: CUREAB GMBHInventors: Frank Stenner-Liewen, Norbert Markuly, Heike Liewen
-
Patent number: 11692035Abstract: Provided are anti-CD47 monoclonal antibodies (anti-CD47 mAbs) with distinct functional profiles as described herein, methods to generate anti-CD47 mAbs, and to methods of using these anti-CD47 mAbs as therapeutics for the prevention and treatment of solid and hematological cancers, ischemia-reperfusion injury, cardiovascular diseases, autoimmune diseases, inflammatory diseases or as diagnostics for determining the level of CD47 in tissue samples.Type: GrantFiled: December 4, 2019Date of Patent: July 4, 2023Assignee: Arch Oncology, Inc.Inventors: Pamela T. Manning, Robyn Puro, Juan C. Almagro, Robert W. Karr
-
Patent number: 11690912Abstract: Compositions and methods for treating rheumatoid arthritis and/or accelerated atherosclerosis are provided, including an inhibitor of oxidized or malondialdehyde-modified low density lipoprotein (LDL) for administration to a subject. Exemplary inhibitors of oxidized LDL include an anti-oxidized LDL antibody, which results in a reduction in the secretion of pro-inflammatory cytokine from primary monocyte in vitro and the plasma cytokine level of inflammatory cytokine in vivo.Type: GrantFiled: May 29, 2019Date of Patent: July 4, 2023Assignee: Abcentra, LLCInventors: Bertrand C. Liang, Stacey Ruiz, Christopher John Farina
-
Patent number: 11690919Abstract: Endolysosomal targeting conjugates that are engineered to deliver cargo molecules such as cytotoxic drugs or imaging labels with improved efficiency to late endosomes and/or lysosomes in target cells such as tumor cells are described. The endolysosomal targeting conjugate includes a targeting component and a cargo component. The targeting component is configured to bind to a cell surface molecule of a target cell and the cargo component includes a cargo molecule. The targeting component and the cargo component may be fused by a covalent bond or associated by a non-covalent bond. The targeting component may bind to the cell surface molecule or the cargo component with higher affinity in the extracellular space than in an endolysosomal compartment of the target cell.Type: GrantFiled: January 17, 2018Date of Patent: July 4, 2023Assignees: The Texas A&M University System, Board of Regents of the University of Texas SystemInventors: Elizabeth Sally Ward Ober, Raimund Johannes Ober, Jeffrey Che-Wei Kang, Wei Sun, Ran Li
-
Patent number: 11680104Abstract: Antibodies, or antigen-binding fragments thereof, that bind to Lymphocyte-activation gene-3 (LAG-3) are described, in particular antibodies, or antigen-binding fragments thereof, that are agonists of LAG-3. The antibodies bind to LAG-3 and inhibit antigen-induced CD4+ and/or CD8+ T cell proliferation, or antigen-induced CD4+ and/or CD8+ T cell activation. The antibodies may be used as medicaments, in particular for the treatment of conditions associated with proliferation and/or activation of CD4+ and/or CD8+ T cells, such as inflammatory and autoimmune disorders.Type: GrantFiled: September 1, 2016Date of Patent: June 20, 2023Assignee: IMMUTEP S.A.S.Inventors: Frédéric Triebel, Chrystelle Brignone
-
Patent number: 11667726Abstract: It is demonstrated herein that inhibitors of immune checkpoints and CHI3L1 are synergistic. Accordingly, described herein are methods and compositions relating to combinatorial therapies for cancer, e.g., comprising an inhibitor of CHI3L1; and an inhibitor of an immune checkpoint protein. In some embodiments, the CHI3L1 inhibitor can be an antibody or antibody reagent as described herein.Type: GrantFiled: July 30, 2020Date of Patent: June 6, 2023Assignee: Brown UniversityInventors: Jack A. Elias, Chun Geun Lee, Chuan Hua He, Bing Ma, Suchitra Kamle, Chang-Min Lee
-
Patent number: 11661449Abstract: This application provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, as well as means and methods for producing them.Type: GrantFiled: October 22, 2021Date of Patent: May 30, 2023Assignee: MedImmune LimitedInventors: Nancy Ulbrandt, Nicole Kallewaard-Lelay, Andy Q. Yuan, Bettina Richter
-
Patent number: 11642394Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.Type: GrantFiled: February 28, 2020Date of Patent: May 9, 2023Assignee: ACCELERON PHARMA INC.Inventors: Ravindra Kumar, Rajasekhar Naga Venkata Sai Suragani
-
Patent number: 11634501Abstract: Provided herein are antibodies and methods of use thereof. The antibodies as disclosed herein bind to CD163+ on cells, such as on macrophages. These antibodies can be used in methods of treatment, such as methods of treating cancer.Type: GrantFiled: July 17, 2020Date of Patent: April 25, 2023Assignee: OncoResponse, Inc.Inventors: Kamal D. Puri, Siddarth Chandrasekaran, Melissa L. Conerly, Peter Probst, Tyrel T. Smith, Mark E. Branum, Randi M. Simmons
-
Patent number: 11634432Abstract: The disclosure provides compounds and salts that show high selectivity and inhibitory activity for mTORC1 and uses thereof for the treatment of disease, such as Formula I: or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 1, 2022Date of Patent: April 25, 2023Assignee: AEOVIAN PHARMACEUTICALS, INC.Inventor: John Kincaid
-
Patent number: 11623917Abstract: The present invention is directed to multi-tyrosine kinase inhibitor compounds. The present invention is further directed to compositions comprising those compounds. Finally, the present invention is directed to methods of treating eye conditions including, but not limited to, diabetic background retinopathy, diabetic macular edema, diabetic proliferative retinopathy, diabetic macular edema with proliferative retinopathy, proliferative fibrovascular disease, diabetic macular edema with proliferative fibrovascular disease, retinopathy of prematurity, dry macular degeneration, dry macular degeneration with drusen and wet macular degeneration, using compounds and compositions of the invention.Type: GrantFiled: December 11, 2020Date of Patent: April 11, 2023Assignee: Ontogenesis, LLCInventor: Gerald Horn
-
Patent number: 11613564Abstract: Provided are methods of treating cancer (e.g., non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), HER2-positive gastric/gastroesophageal junction (GEJ) cancer, de novo or transformed diffuse large B cell lymphoma (DLBCL), or indolent lymphoma) in an individual that comprise administering to the individual (a) a polypeptide comprising a SIRP? D1 domain variant and an Fc domain variant, and (b) an anti-cancer antibody (e.g., an anti-PD1 antibody, anti-HER2 antibody, or an anti-CD20 antibody). Also provided are related kits pharmaceutical compositions.Type: GrantFiled: May 28, 2020Date of Patent: March 28, 2023Assignee: ALX Oncology Inc.Inventors: Jaume Pons, Hong Wan, Sophia Randolph
-
Patent number: 11596683Abstract: Engineered Influenza polynucleotides, viruses, vaccines, and methods of making and using the same are provided. More specifically, the present inventors have developed replication competent engineered influenza viruses having, for example, a modified segment 4 and/or segment 6 that include at least one additional polynucleotide encoding a heterologous polypeptide.Type: GrantFiled: July 12, 2017Date of Patent: March 7, 2023Assignee: Duke UniversityInventors: Nicholas Scott Heaton, Alfred Theodore Harding, Brook Elizabeth Heaton
-
Patent number: 11578137Abstract: This invention relates to inhibition of the complement signaling using an anti-C5 antibody. Specifically, the invention relates to methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the individual with an anti-C5 antibody.Type: GrantFiled: March 6, 2018Date of Patent: February 14, 2023Assignee: The Trustees of the University of PennsylvaniaInventors: Wenchao Song, Sayaka Sato, Takashi Miwa, Damodar Gullipalli
-
Patent number: 11564987Abstract: The present invention concerns a method for treating triple-negative breast cancer (TNBC) in an individual, and/or for inducing an immune response to HER2/neu in an individual with a triple-negative breast cancer expressing low levels of HER2/neu, the method comprising administering to the individual: (a) an effective amount of trastuzumab, or derivative thereof; and (b) an effective amount of nelipepimut-S, or variant thereof, optionally with an immunological adjuvant. Preferably, the method includes a preparatory or priming phase comprising a frequency and duration of trastuzumab or trastuzumab derivative administration sufficient to substantially increase the major histocompatibility complex (MHC)-mediated presentation of HER2 peptide fragments to the patient immune system. The invention also includes medicaments and kits for treating TNBC in an individual, and/or for inducing an immune response to HER2/neu in an individual with a TNBC expressing HER2/neu.Type: GrantFiled: October 19, 2019Date of Patent: January 31, 2023Assignee: SLSG LIMITED LLCInventors: George E. Peoples, Angelos M. Stergiou, Nicholas J. Sarlis
-
Patent number: 11566080Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.Type: GrantFiled: February 5, 2020Date of Patent: January 31, 2023Assignee: Xencor, Inc.Inventors: John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
-
Patent number: 11567077Abstract: The present invention is directed to particular monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of Streptococcus pneumoniae infections. In particular, these antibodies may kill Streptococcus pneumoniae or limit the replication of Streptococcus pneumoniae. Also disclosed are improved methods for producing such monoclonal antibodies.Type: GrantFiled: March 2, 2016Date of Patent: January 31, 2023Assignee: Oklahoma Medical Research FoundationInventor: Kenneth Smith